Document is current
Any future updates will be listed below
-
Authors
Giuliano, Loretta https://orcid.org/0000-0003-2512-6972
Zambrelli, Elena
Durante, Vania
Battaglia, Giulia
Nucera, Bruna
Mastrangelo, Vincenzo
Pappalardo, Irene
Ranzato, Federica
Cerulli Irelli, Emanuele
Mostacci, Barbara
,
- License Information
-
More Information
Article History
Received: 4 June 2025
Revised: 2 July 2025
Accepted: 3 July 2025
First Online: 18 July 2025
Declarations
:
: LG has received personal fees from Angelini Pharma, Lusofarmaco, Eisai, Ecupharma. EZ has personal fees from Eisai, Angelini Pharma, Lusofarmaco, Italfarmaco, Eisai, and Jazz Pharma. BN has received personal fees from Angelini and Dr. Schär. IP has received personal fees from Eisai and Angelini. FR has received personal received speaker fees from Eisai, UCB, and Angelini. ECI has received ECI has received speaking honoraria from Angelini Pharma. BM has received personal fees from Livanova, Angelini, Eisai, Lusofarmaco, Sanofi; and has served as an investigator in trials for which her institution received compensation from Livanova, Xenon, Takeda and BioHaven outside the submitted work. The authors VD, GB, VM, have no relevant financial interests to disclose.
: Not applicable.
: Not applicable.
: Not applicable.
